Emerging Strategies in Bone Health Management for the Adjuvant Patient
- 31 December 2007
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 34, S11-S16
- https://doi.org/10.1053/j.seminoncol.2007.10.003
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- In vivo perspective study about the effects of weekly low dose administration of zoledronic acid (ZA) on angiogenesisJournal of Clinical Oncology, 2007
- The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugsProceedings of the National Academy of Sciences, 2006
- An amino-bisphosphonate targets MMP-9–expressing macrophages and angiogenesis to impair cervical carcinogenesisJournal of Clinical Investigation, 2004
- Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylationBJU International, 2004
- New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effectsBritish Journal of Cancer, 2003
- Zoledronic Acid Treatment of 5T2MM-Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased SurvivalJournal of Bone and Mineral Research, 2003
- Metastasis to bone: causes, consequences and therapeutic opportunitiesNature Reviews Cancer, 2002
- Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivoBritish Journal of Cancer, 2002
- Early Detection of Bone Metastases in a Murine Model Using Fluorescent Human Breast Cancer Cells: Application to the Use of the Bisphosphonate Zoledronic Acid in the Treatment of Osteolytic LesionsJournal of Bone and Mineral Research, 2001
- Cellular and molecular mechanisms of action of bisphosphonatesCancer, 2000